Equity · Healthcare
HALO
NASDAQHalozyme Therapeutics (HALO)
The line runs 102.59 USD on 10 August through 103.69 USD on 6 November, on a scale from 80 to 140. Days the market did not trade hold the previous close, flat.
- Market cap
- 11.8B USD
- P/E (TTM)
- 25.9
- Revenue, year to Dec 2025
- 1.4B USD
- EPS, diluted, year to Dec 2025
- 2.56 USD
- 52-week range
- 61.87 USD – 131.12 USD
- Avg volume
- 138.2K
- Mentions, 30 days
- 44
- Net sentiment
- +0.06
as of Nov 6, 2026
Have Halozyme Therapeutics (HALO) insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, Halozyme Therapeutics insiders reported 12 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 2 Mar 2026, show no open-market purchase.
Form 4, 90 days to 9 Nov 2026, newest reported trade 8 Oct 2026
Buys 0Sells 12Net sold $22.10MOther filings 11
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 08 Oct 2026 | Torley HelenPRESIDENT AND CEO | Sell | 20,000 | 2.2M USD |
| 07 Oct 2026 | Torley HelenPRESIDENT AND CEO | Sell | 20,000 | 2.2M USD |
| 06 Oct 2026 | Torley HelenPRESIDENT AND CEO | Sell | 20,000 | 2.2M USD |
| 01 Oct 2026 | Posard Matthew L.Director | Sell | 5,230 | 568K USD |
| 16 Sep 2026 | Posard Matthew L.Director | Sell | 18,996 | 2.0M USD |
| 11 Sep 2026 | Torley HelenPRESIDENT AND CEO | Sell | 20,000 | 2.1M USD |
| 10 Sep 2026 | Torley HelenPRESIDENT AND CEO | Sell | 20,000 | 2.1M USD |
| 09 Sep 2026 | Torley HelenPRESIDENT AND CEO | Sell | 20,000 | 2.1M USD |
| 19 Aug 2026 | Torley HelenPRESIDENT AND CEO | Sell | 20,000 | 2.1M USD |
| 18 Aug 2026 | Torley HelenPRESIDENT AND CEO | Sell | 20,000 | 2.1M USD |
| 17 Aug 2026 | Torley HelenPRESIDENT AND CEO | Sell | 20,000 | 2.1M USD |
| 10 Aug 2026 | Connaughton BernadetteDirector | Sell | 1,626 | 167K USD |
| Sold | 12 open-market sales | 205,852 | $22.10M |
11 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 08 Oct 2026 | Torley HelenPRESIDENT AND CEO | Option exercise | 20,000 | 368K USD |
| 07 Oct 2026 | Torley HelenPRESIDENT AND CEO | Option exercise | 20,000 | 368K USD |
| 06 Oct 2026 | Torley HelenPRESIDENT AND CEO | Option exercise | 20,000 | 368K USD |
| 01 Oct 2026 | Daly James MDirector | Award | 1,169 | |
| 11 Sep 2026 | Torley HelenPRESIDENT AND CEO | Option exercise | 20,000 | 368K USD |
| 10 Sep 2026 | Torley HelenPRESIDENT AND CEO | Option exercise | 20,000 | 368K USD |
| 09 Sep 2026 | Torley HelenPRESIDENT AND CEO | Option exercise | 20,000 | 368K USD |
| 01 Sep 2026 | Appelhans DannielleDirector | Award | 1,161 | |
| 19 Aug 2026 | Torley HelenPRESIDENT AND CEO | Option exercise | 20,000 | 368K USD |
| 18 Aug 2026 | Torley HelenPRESIDENT AND CEO | Option exercise | 20,000 | 368K USD |
| 17 Aug 2026 | Torley HelenPRESIDENT AND CEO | Option exercise | 20,000 | 368K USD |
Which funds hold Halozyme Therapeutics (HALO)?
0 of the 45 institutional funds we track reported a Halozyme Therapeutics position for the quarter ended 30 Sep 2026; the latest of those filings landed 06 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | Exited |
Have members of Congress traded Halozyme Therapeutics (HALO)?
The most recent congressional trade disclosed in Halozyme Therapeutics is a sale by Gilbert Ray Cisneros, Jr. (house, CA), dated 29 Sep 2026.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 29 Sep 2026 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Sale | 1K USD–15K USD | 13 days |
| 24 Mar 2025 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Sale | 1K USD–15K USD | 14 days |
| 09 Sep 2024 | Josh Gottheimerhouse · Democrat–NJ | Sale | 1K USD–15K USD | 24 days |
| 06 Dec 2022 | Josh Gottheimerhouse · Democrat–NJ | Sale | 1K USD–15K USD | 38 days |
| 05 Aug 2022 | Josh Gottheimerhouse · Democrat–NJ | Sale | 1K USD–15K USD | 42 days |
| 20 Aug 2021 | Josh Gottheimerhouse · Democrat–NJ | Purchase | 1K USD–15K USD | 31 days |
| 19 Oct 2020 | Josh Gottheimerhouse · Democrat–NJ | Purchase | 1K USD–15K USD | 17 days |
What has been filed or recorded for Halozyme Therapeutics (HALO)?
The filings we hold for Halozyme Therapeutics, newest first: 6 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 09 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 929 shares | 102K USD notional · 0.001% of shares out |
| 07 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,201 shares | 132K USD notional · 0.001% of shares out |
| 06 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,303 shares | 141K USD notional · 0.001% of shares out |
| 05 Oct 2026 | Fails to deliver | Shares failed to deliver | 2,568 shares | 282K USD notional · 0.002% of shares out |
| 02 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,500 shares | 160K USD notional · 0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 2.01 USD | |
| 30 Sep 2026 | Financials | Total assets | 3.5B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | −55.2M USD | at period end |
| 29 Sep 2026 | Fails to deliver | Shares failed to deliver | 64 shares | 7K USD notional · <0.001% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 1.90 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 1.22 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 2.56 USD | |
| 31 Dec 2025 | Financials | Revenue | 1.4B USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 316.9M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 2.56 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 1.43 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 1.33 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 0.93 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS 3.43 USD |
What is Reddit saying about Halozyme Therapeutics (HALO)?
Reddit mentioned HALO 44 times in the 30 days to 8 November 2026, across 3 of the communities we track. All of them were scored for sentiment: 48% read bullish, 7% bearish and 45% neither. Reddit data updated 8 November 2026.
30-day window, Method
Mentions, 30 days 44Bullish 48%Bearish 7%Communities 3Against the market −6 points
How do Reddit mentions of Halozyme Therapeutics (HALO) compare with its price?
Share ↗
Where Halozyme Therapeutics (HALO) is discussed
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/wallstreetbets | 95% | 42 | +0.06 |
| r/ausfinance | 2% | 1 | +0.03 |
| r/stocks | 2% | 1 | +0.19 |
Moves with Halozyme Therapeutics (HALO)
Tickers whose daily Reddit volume rose and fell with Halozyme Therapeutics (HALO)'s. Co-discussion, not price.
FEAT +0.94MARS CRUDE +0.93HYDROGEN +0.91SHEL +0.89NKLA +0.89MIST +0.88
How closely daily Reddit mention counts rose and fell together over the last 30 days (31 daily observations), Method
Halozyme Therapeutics (HALO): frequently asked questions
What did Halozyme Therapeutics shares close at?
Halozyme Therapeutics closed at 103.69 USD on 6 Nov 2026, down 9.04% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Halozyme Therapeutics’ market cap?
Halozyme Therapeutics is worth 11.8B USD by market value as of 6 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Halozyme Therapeutics’ P/E ratio?
Halozyme Therapeutics has a price-to-earnings ratio of 25.9, as of 6 Nov 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Halozyme Therapeutics’ revenue?
Halozyme Therapeutics reported revenue of 1.4B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Halozyme Therapeutics insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, Halozyme Therapeutics insiders reported 12 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 2 Mar 2026, show no open-market purchase. A further 11 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Halozyme Therapeutics?
0 of the 45 funds we track reported a Halozyme Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds
Have members of Congress traded Halozyme Therapeutics?
Yes. 7 trades in Halozyme Therapeutics appear in the congressional disclosures we hold; the latest is a sale by Gilbert Ray Cisneros, Jr. (House, CA) dated 29 Sep 2026, filed 12 Oct 2026. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Halozyme Therapeutics last report earnings?
Halozyme Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 2.01 USD; no next date is announced in SEC filings yet. See Filings
What is Reddit saying about Halozyme Therapeutics?
Halozyme Therapeutics was mentioned 2 times in the last 7 days across the finance subreddits we track, and 44 times over the trailing 30 days. Of the 44 mentions scored for sentiment, 48% read bullish and 7% bearish. That is a social signal, not investment advice. See Reddit
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings